Evidence map›Paper›PMID 35324790›Full record

ReviewBioengineering (Basel, Switzerland)2022

Smartphone-Based Biosensor Devices for Healthcare: Technologies, Trends, and Adoption by End-Users.

Rossana E Madrid, Fernando Ashur Ramallo, Daniela E Barraza, Roberto E Chaile

Open access · goldAbstract readReview
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Engineering Stimuli-Responsive Materials for Precision Medicine.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rossana E MadridLaboratorio de Medios e Interfases (LAMEIN), DBI, FACET, Universidad Nacional de Tucumán, Instituto Superior de Investigaciones Biológicas (INSIBIO), CONICET, Av. Independencia 1800, San Miguel de Tucuman 4000, Argentina.ORCID 0000-0003-1664-7901
Fernando Ashur RamalloLaboratorio de Medios e Interfases (LAMEIN), DBI, FACET, Universidad Nacional de Tucumán, Instituto Superior de Investigaciones Biológicas (INSIBIO), CONICET, Av. Independencia 1800, San Miguel de Tucuman 4000, Argentina.
Daniela E BarrazaLaboratorio de Medios e Interfases (LAMEIN), DBI, FACET, Universidad Nacional de Tucumán, Instituto Superior de Investigaciones Biológicas (INSIBIO), CONICET, Av. Independencia 1800, San Miguel de Tucuman 4000, Argentina.
Roberto E ChaileLaboratorio de Medios e Interfases (LAMEIN), DBI, FACET, Universidad Nacional de Tucumán, Instituto Superior de Investigaciones Biológicas (INSIBIO), CONICET, Av. Independencia 1800, San Miguel de Tucuman 4000, Argentina.
National University of Tucumán · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smart biosensors are becoming an important support for modern healthcare, even more so in the current context. Numerous smartphone-based biosensor developments were published in recent years, some highly effective and sensitive. However, when patents and patent applications related to smart biosensors for healthcare applications are analyzed, it is surprising to note that, after significant growth in the first half of the decade, the number of applications filed has decreased considerably in recent years. There can be many causes of this effect. In this review, we present the state of the art of different types of smartphone-based biosensors, considering their stages of development. In the second part, a critical analysis of the possible reasons why many technologies do not reach the market is presented. Both technical and end-user adoption limitations were addressed. It was observed that smart biosensors on the commercial stage are still scarce despite the great evolution that these technologies have experienced, which shows the need to strengthen the stages of transfer, application, and adoption of technologies by end-users.

Indexed as

commercial biosensorselectrochemical biosensorsoptical biosensorspaper-based biosensorsPOC devicesregulations

Identifiers

PMID35324790
PMCPMC8945789
OpenAlexW4214862284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.